SharonLReedMD

Professor, Pathology, UCSD School of Medicine

Dr. Reed is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
UCSD School of Medicine
9500 Gilman Dr
La Jolla, CA 92093
Phone+1 858-822-2808

Fax+1 619-543-6614

University of California (San Diego) Medical CenterResidency, Internal Medicine, 1979 - 1984
Icahn School of Medicine at Mount Sinai/Morningside/WestInternship, Internal Medicine, 1978 - 1979
Harvard Medical SchoolClass of 1978
University of California (San Diego) Medical CenterFellowship, Infectious Disease

PubMed

653 citations
Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection
Robert T. Schooley, Biswajit Biswas, Jason J. Gill, Adriana Hernandez-Morales, Jacob C. Lancaster
Antimicrobial Agents and Chemotherapy. 2017-10-01
52 citations
Commercial Serology Assays Predict Neutralization Activity Against SARS-CoV-2.
Raymond T. Suhandynata, Melissa A Hoffman, Deli Huang, Jenny Tuyet Tran, Michael J. Kelner
Clinical Chemistry. 2021-01-30
65 citations
Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy.
Jeffrey D. Jenks, Sharon L. Reed, Danila Seidel, Philipp Koehler, Oliver A. Cornely
International Journal of Antimicrobial Agents. 2018-11-01

Journal Articles

Rare Mold Infections Caused by Mucorales, Lomentospora Prolificans and Fusarium, San Diego: The Role of Antifungal Combination Therapy
Jeffrey D Jenks, Sharon L Reed, Sanjay R Mehta, International Journal of Antimicrobial Agents

UC San Diego Partners with Diagnostics Manufacturers for COVID-19 Testing; Begins Trial to Assess Antiviral DrugMarch 28th, 2020

Novel Therapeutics For Class B ProtozoaNational Institute Of Allergy And Infectious Diseases2008–2012
Genetic Manipulation Of Entamoeba VirulenceNational Institute Of Allergy And Infectious Diseases2001–2005
Interactions Of E Histolytica With Host Mucosal DefensesNational Institute Of Diabetes And Digestive And Kidney Diseases1998–2002
Protease Inhibitors--Novel Drug Therapy For T GondiiNational Institute Of Allergy And Infectious Diseases1998–2001
Cysteine Proteinases And Virulence Of E. HistolyticaNational Institute Of Allergy And Infectious Diseases2000
Cysteine Proteinases And Virulence Of E HistolyticaNational Institute Of Allergy And Infectious Diseases1995–1998
Cysteine Proteinases And Virulence Of E. HistolyticaNational Institute Of Allergy And Infectious Diseases1990–1992